Roy S Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital ; Associate Director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center

Physician Biography

Dr. Herbst is a professor of Medicine and Pharmacology, Chief of the Medical Oncology and Associate Director for Translational Science at Yale School of Medicine and Yale Cancer Center (YCC). Prior to his appointment at Yale, Herbst was a professor of medicine, chief of the Section of Thoracic Medical Oncology, and the Barnhart Family Distinguished Professor in Targeted Therapies at MD Anderson Cancer Center. His primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients.

Dr. Herbst’s laboratory work is focused on angiogenesis and dual EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from the preclinical to clinical setting in multiple phase II and III studies which he has led. He has led the Phase I development of several of the new generation of targeted agents for NSCLC, including gefitinib, erlotinib, and bevacizumab. He co-led the BATTLE-1 effort at M.D. Anderson Cancer Center and now leads the BATTLE-2 clinical program at Yale. He serves as a Co-Program Leader of the Developmental Therapeutics Program at YCC.

Dr. Herbst is a member of the National Cancer Policy Forum for which he has organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored more than 200 peer-reviewed papers and has current grant funding for his work from numerous sources including the National Cancer Institute, AACR and multiple charitable foundations.

After earning a B.S. and M.S. from Yale University summa cum laude, he received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from the Rockefeller University. Dr. Herbst completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Thoracic Oncology Program

Yale Cancer Center: Thoracic Oncology Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Medical Oncology AB of Internal Medicine (1997)

Clinical Trials

Conditions Study Title
Lung A phase II study of combination immunotherapy with ipilimumab and nivolumab in patients with advanced non-small cell lung cancer resistant to anti-PD-1-axis therapy
Phase I An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Lung A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
Lung A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer
Lung Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy
Lung An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Lung Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Lung Personalized Prevention: Smoking Cessation in Patients With a Lung Nodule
Lung Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Lung A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Lung Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Lung, Melanoma, skin MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Lung Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Lung Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Edit this profile